Analyst Ratings For Aimmune Therapeutics (NASDAQ:AIMT)
Today, Royal Bank of Canada initiated coverage on Aimmune Therapeutics (NASDAQ:AIMT) with a Outperform with a price target of $55.00.
Some recent analyst ratings include
- 2/7/2018-Royal Bank of Canada initiated coverage with a Outperform rating.
- 12/20/2017-Robert W. Baird initiated coverage with a Outperform rating.
- 12/12/2017-Cantor Fitzgerald initiated coverage with a Overweight rating.
- 12/1/2017-Wedbush Reiterated Rating of Outperform.
Recent Insider Trading Activity For Aimmune Therapeutics (NASDAQ:AIMT)
Aimmune Therapeutics (NASDAQ:AIMT) has insider ownership of 17.59% and institutional ownership of 73.54%.
- On 12/27/2018 Daniel C Md Adelman, Insider, sold 3,283 with an average share price of $40.00 per share and the total transaction amounting to $131,320.00.
- On 2/1/2018 Mary M Rozenman, Insider, sold 6,592 with an average share price of $35.36 per share and the total transaction amounting to $233,093.12.
- On 1/24/2018 Douglas T Sheehy, Insider, sold 1,875 with an average share price of $38.15 per share and the total transaction amounting to $71,531.25.
- On 1/16/2018 Daniel C Md Adelman, Insider, sold 9,933 with an average share price of $40.00 per share and the total transaction amounting to $397,320.00.
- On 1/12/2018 Daniel C Md Adelman, Insider, sold 26,784 with an average share price of $40.00 per share and the total transaction amounting to $1,071,360.00.
- On 1/4/2018 Douglas T Sheehy, Insider, sold 1,648 with an average share price of $37.33 per share and the total transaction amounting to $61,519.84.
- On 1/2/2018 Susan E Barrowcliffe, Insider, sold 75,000 with an average share price of $37.14 per share and the total transaction amounting to $2,785,500.00.
Recent Trading Activity for Aimmune Therapeutics (NASDAQ:AIMT)
Shares of Aimmune Therapeutics closed the previous trading session at 37.93 up +2.13 5.95% with shares trading hands.